shutterstock_512649

Merck KGaA to flog Allergopharma business to Dermapharm

pharmafile | February 21, 2020 | News story | Medical Communications, Sales and Marketing Allergopharma, Dermapharm, Merck KGaA, pharma 

German-based drugmaker Merck KGaA has confirmed its intention to divest its allergy business Allergopharma to Dermapharm, another German manufacturer of generics, dietary products, cosmetics and medical devices.

The business unit generated €88 million for Merck in 2018. It is currently developing a competitor to Mylan’s flagship EpiPen epinephrine autoinjector as a treatment for anaphylactic reactions.

The agreement includes Allergopharma’s therapeutic and diagnostic portfolio, but also its production site located in Reinbek, Germany.

The value of the sale was not disclosed, but Merck’s share price rose 1.34% on announcement of the news, while Dermapharm’s rose by 3.05%.

It was confirmed that the deal is expected to close in the second quarter of this year, subject to regulatory approval and satisfaction of closing conditions.

Matt Fellows

Related Content

Exscientia enters AI drug discovery collaboration with Merck KGaA

Exscientia has announced a new collaboration with Merck KGaA, Darmstadt, Germany, with a focus on …

FDA approves IMIDEX’s AI-powered device VisiRad XR

The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …

Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo

On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …

Latest content